I think that's doable.
I have a pps target of $4
Could go higher, I hope. A note of caution: STXS has sequential quarter-over-quarter growth rate of -3%.
The company is also battling some cash flow restraints, with cash levels struggling to keep up with current liabilities ($8.5M against $12.8M, respectively).
Increase sales revenue is a must!
News: $STXS The Daily Buzz: The Action Starts to Heat Up (CRWD, TCNNF, STXS)
Crowdstrike Holdings Inc (NASDAQ:CRWD) is an interesting stock seeing some recent declines in front of earnings on later today (Thursday). This is one of the most dramatic traders’ stocks in the market thus far in 2019, with wide swings and plenty of liquidity on a regular basis. ...
Find out more STXS - The Daily Buzz: The Action Starts to Heat Up (CRWD, TCNNF, STXS)
Find the right chart and follow the patience rule and this is what happens. STXS used to be a nasdaq and now it’s an otc monster
Reading the Seeking Alpha article, it is obvious that this stock is trading at a huge discount right now.
STXS was up 20 percent today in anticipation of going on the American stock exchange on Friday.
Continued selling pressure due to the $25M conversion of preferred shares increasing the common share float. In effect, the placement was made to compensate the participating executives and directors which sends a signal to investors that this is a good time to sell.
The point is that the key statements in your post were incorrect. Insiders were not selling shares.
I agree that the sell-off at the time came from the word of the placement leaking.
It might be old news to you but the SEC filing was dated "STEREOTAXIS, INC. - D (Filed: 21-08-2019)." However, some people knew about this in mid-July which accounts for the sell-off at that time.
No, you are reading the filing incorrectly. This is the recording of the $25,000,000 placement through Cowen from August 7! Old news.
Won't be long before the international conference at the beginning of September. Hoping for the announcement of EU sales of the Genesis soon after.
STXS robotic technology has better acceptance overseas, e.g., Japan, Costa Rica, Panama, and countries that promote medical tourism. Eventually this success will spill over to the United States and Europe.
Did the company give guidance on capital sales? Seems to be stuck at zero and I am not sure what the Genesis system does that the older system would not that would entice replacement sales. The best thing to occur would be if they can sell systems to major centers that don't have them now and there are still many of those that insist that manual is better.
News: $STXS Stereotaxis Reports 2019 Second Quarter Financial Results
ST. LOUIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2019. In a separate press release issued concurre...
Got this from Stereotaxis Reports 2019 Second Quarter Financial Results
News: $STXS Stereotaxis Announces $25 Million Private Placement
ST. LOUIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with select institutional investors for a $25 m...
In case you are interested Stereotaxis Announces $25 Million Private Placement
News: $STXS Society for Cardiac Robotic Navigation to Showcase Stereotaxis Clinical Value & Technology
ST. LOUIS, July 31, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will participate in the Society for Cardiac Robotic Navigation’s 4th Annual Meeting , ...
Find out more Society for Cardiac Robotic Navigation to Showcase Stereotaxis Clinical Value & Technology
Well the breakout was temporary.... It's now lost 1/3 of its value. Something stinky happened!
News: $STXS Stereotaxis to Highlight Latest Techniques for Performing Robotic Ablations at European Heart Rhythm Association Annual Congress March 17-19
ST. LOUIS, March 15, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will be attending the European Heart Rhythm Association (EHRA) Annual Congress from March 17-...
Find out more https://marketwirenews.com/news-releases/stereotaxis-to-highlight-latest-techniques-for-performing-robotic-ablations-at-european-heart-rhythm-association-annual-congress-march-17-19-7850774.html
News: $STXS Stereotaxis and Acutus Medical Combine Robotic Precision and High-Resolution Imaging to Treat Arrhythmias in First Integrated Procedures
ST. LOUIS and CARLSBAD, Calif. , March 15, 2019 /PRNewswire/ -- Stereotaxis (OTCQX: STXS) and Acutus Medical today announced the first patients have been successfully treated utilizing integrated Stereotaxis Robotic Magnetic Navigation and Acutus AcQMap systems. The integr...
Find out more https://marketwirenews.com/news-releases/stereotaxis-and-acutus-medical-combine-robotic-precision-and-high-resolution-imaging-to-treat-arrhythmias-in-first-integrated-procedures-7850366.html
RMN found to be compatible with LVAD (Impella, Abiomed) for VT ablation in hemodynamically unstable patient. First attempt and successful outcome. Have not been tried before because there were fears of incompatibility of Impella inside magnetic field. There was no other way to save him as manual ablation attempts failed (impossible to navigate to required locations).
News: $STXS Stereotaxis Reports 2018 Full Year Financial Results
Record high annual recurring revenue of $27.8 million; 3% annual growth Positive annual net income for the first time in Company history despite significantly increased R&D investments Innovation initiatives to be showcased in May at Heart Rhythm Society meeting Strong financial po...
Find out more https://marketwirenews.com/news-releases/stereotaxis-reports-2018-full-year-financial-results-7831046.html
Haven;t looked at this for a while. What's up with the Acutus collaboration? Anyone?
Ablation of PVC/VT following and through artificial aortic valve placement. Many HF patients have these, not many are equipped or skilled to deal with them.
Stereotaxis, Inc. is engaged in designing , manufacturing and marketing the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital's interventional surgical suite, or interventional lab. The Epoch Solution is consists of the Niobe ES Robotic Magnetic Navigation System (Niobe ES system), Odyssey Information Management Solution (Odyssey Solution), and the Vdrive Robotic Navigation System. The Company has alliances with Siemens, Philips and Biosense Webster. The Company has regulatory clearance, licensing and/or CE Mark approvals to market the Niobe Robotic Magnetic Navigation System, the Cardiodrive automated catheter advancement system, and various disposable interventional devices in the United States, Canada, Europe, China and various other countries.
Niobe ES Robotic Magnetic Navigation System
The Company’s Niobe ES robotic system provides the physician with remote digital instrument control through point and click computer mouse control, in combination with image integration and three dimensional (3D) reconstruction. It can be operated either from beside the patient table, as in traditional interventional procedures, or from a room adjacent to the patient and outside the x-ray fluoroscopy field. The Niobe ES robotic system allows the operator to navigate disposable interventional devices to the treatment site through paths in the blood vessels and chambers of the heart to deliver treatment by using computer controlled, externally applied magnetic fields to directly govern the motion of the working tip of these devices, each of which has a magnetically sensitive tip that predictably responds to magnetic fields generated by its system.
The Company has integrated its Niobe ES robotic system with Siemens’ and with Philips’ digital x-ray fluoroscopy systems. In addition, it have integrated the Niobe ES robotic system with Biosense Webster’s 3D catheter location sensing technology to provide real-time information as to the 3D location of the working tip of the instrument, and with Biosense Webster’s ablation tip technology. The components of the Niobe ES robotic system are Niobe Robotic Magnetic Navigation System, which utilizes two permanent magnets mounted on articulating and pivoting arms that are enclosed within a stationary housing, with one magnet on either side of the patient table. The Niobe ES robotic system is indicated for use in cardiac, peripheral and neurovascular applications and Cardiodrive Automated Catheter Advancement System, as the physician conducts the procedure from the adjacent control room, the Cardiodrive or QuikCAS automated catheter advancement systems are used to remotely advance and retract the electrophysiology catheter in the patient’s heart while the Niobe magnets steer the working tip of the device.
The Odyssey Solution offers a fully integrated, real-time information solution to manage, control, record and share procedures across networks or around the world. Through the use of a single mouse and keyboard, the Odyssey Solution allows the user to command multiple systems in the lab from a single point of control. In addition, the Odyssey Solution acquires a real-time, remote view of the lab capturing synchronized procedure data for review of important events during cases. The Odyssey Solution enables physicians to access recorded cases and create snapshots following procedures for enhanced clinical reporting, auditing and presentation. The Odyssey Solution enables physicians to establish a master archive of procedures performed in the lab providing a tool for training new staff on the standard practices. The Odyssey Solution further enables procedures to be observed remotely around the world with Internet access over a hospital VPN even wirelessly using a standard laptop or Windows tablet computer.
Vdrive Robotic Navigation System
The Vdrive Robotic Navigation System and Niobe ES robotic system provide independent remote manipulation of diagnostic catheters and magnetic ablation catheters in a single interface. The Vdrive Robotic Navigation System provides navigation and stability for diagnostic and ablation devices designed with features to assist in the delivery of better ablations. Features include complementing the Niobe ES control of catheters for fully remote procedures; enabling fully remote, single operator workflow; and providing robotic control of diagnostic devices independent of magnetic navigation. The Vdrive Duo system is an optional expansion of the Vdrive hardware that allows control of the V-loop device and either V-CAS or V-CAS Deflect devices in the same procedure, with a single user interface.
Disposables and Other Accessories
The Company’s Niobe system is designed to use a toolkit of disposable interventional devices. The toolkit consists of Cardiodrive or QuikCAS, which is automated catheter advancement disposables designed to provide e remote advancement of electrophysiology catheters; Cronus, Assert, Titan and Pegasus coronary guidewires, which is designed for use in interventional cardiology procedures for the introduction and placement of over-the-wire therapeutic devices, such as stents and angioplasty balloons; and Biosense Webster’s CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL and CELSIUS RMT THERMOCOOL Irrigated Tip Diagnostic/Ablation Steerable Tip Catheters co-developed by Biosense Webster and Stereotaxis.
In addition to the Vdrive and Vdrive Duo systems, The Company also manufacture and market various disposable components, including V-CAS catheter advancement system that controls both the magnetic catheter body and a standard fixed-curve sheath; V-loop circular catheter manipulator, which allows the user to control certain circular mapping catheters, such as Biosense Webster’s LASSO2515 or LASSO2515 NAV Circular Mapping Catheter, and advance, retract, rotate, deflect and adjust loop radius, all without leaving the control room and V-CAS Deflect fully integrated catheter advancement system with a robotic deflectable sheath for